Understanding Engagement Trends in Chondrosarcoma Clinical Trials
NCT06029478 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-09-08
Summary
Taking part in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.
This study will admit a wide range of data on the clinical trial experience of chondrosarcoma patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.
It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future chondrosarcoma patients.
Conditions
- Chondrosarcoma
Sponsors & Collaborators
-
Power Life Sciences Inc.
lead INDUSTRY
Principal Investigators
-
Michael B Gill · Power Life Sciences Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-31
- Primary Completion
- 2025-10-31
- Completion
- 2026-10-31
Countries
- United States
Study Locations
More Related Trials
-
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
NCT02030964 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II High-Dose Cyclophosphamide for Multiple Sclerosis
NCT00296205 ·Status: WITHDRAWN ·Phase: PHASE2
-
Etoposide and Celecoxib in Patients With Advanced Cancer
NCT00551005 ·Status: COMPLETED ·Phase: PHASE1
-
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
NCT00052611 ·Status: COMPLETED ·Phase: PHASE2
-
Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses
NCT03185871 ·Status: WITHDRAWN ·Phase: PHASE2
-
Clinical Trial on Ganoderma Spore Lipids Combined With Chemo in Patients With G.I. Cancers
NCT02785523 ·Status: UNKNOWN ·Phase: PHASE3
-
Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome
NCT00023621 ·Status: COMPLETED ·Phase: PHASE2
-
Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses
NCT00027976 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer
NCT01284504 ·Status: TERMINATED ·Phase: NA
-
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
NCT00093678 ·Status: WITHDRAWN ·Phase: NA
-
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
NCT07174427 ·Status: RECRUITING ·Phase: PHASE3
-
Mychoice: Testing an Interactive mHealth Tool
NCT03427177 ·Status: COMPLETED ·Phase: NA
-
Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS/ME)
NCT03773003 ·Status: RECRUITING ·Phase: NA
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
NCT06063486 ·Status: RECRUITING ·Phase: PHASE2
-
Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
NCT02520245 ·Status: WITHDRAWN ·Phase: PHASE1
-
Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery
NCT00450736 ·Status: COMPLETED ·Phase: PHASE1
-
Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
NCT06240754 ·Status: RECRUITING ·Phase: PHASE2
-
Curcumin Biomarker Trial in Head and Neck Cancer
NCT01160302 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
NCT06025851 ·Status: COMPLETED ·Phase: PHASE1
-
Celecoxib in Preventing Skin Cancer
NCT00025051 ·Status: WITHDRAWN ·Phase: PHASE2
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
NCT04079179 ·Status: RECRUITING ·Phase: PHASE2
-
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
NCT02839720 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
NCT06987708 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease
NCT00541164 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003
NCT01099267 ·Status: COMPLETED